Neoadjuvant FOLFIRINOX versus Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: Update on the Nationwide Multicenter PREOPANC-2 Randomized Trial
Abstract
Background: Two randomized studies have found superior R0 resection rate with neoadjuvant chemotherapy compared to upfront surgery for (borderline) resectable pancreatic cancer. The PREOPANC-2 trial compares two neoadjuvant regimens in patients with resectable and borderline resectable pancreatic cancer ((B)RPC). Material and methods: This multicenter randomized controlled trial includes patients with pathologically proven pancreatic cancer, WHO...
Paper Details
Title
Neoadjuvant FOLFIRINOX versus Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: Update on the Nationwide Multicenter PREOPANC-2 Randomized Trial
Published Date
Jan 1, 2021
Journal
Volume
23
Pages
S9 - S10
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History